Pulse Biosciences (NASDAQ:PLSE) CEO Paul Laviolette Acquires 15,000 Shares

Pulse Biosciences, Inc (NASDAQ:PLSE) CEO Paul Laviolette acquired 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $19.69 per share, with a total value of $295,350.00. Following the completion of the acquisition, the chief executive officer owned 15,000 shares in the company, valued at $295,350. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Pulse Biosciences Stock Performance

PLSE remained flat at $19.08 on Monday. 953,297 shares of the company traded hands, compared to its average volume of 318,598. The stock’s 50 day simple moving average is $20.85 and its 200 day simple moving average is $17.59. Pulse Biosciences, Inc has a 52 week low of $12.56 and a 52 week high of $26.30. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -17.35 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.05. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.25 million. Research analysts anticipate that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on PLSE. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Oppenheimer reissued an “outperform” rating and issued a $30.00 price target on shares of Pulse Biosciences in a report on Friday, February 20th. Mizuho set a $30.00 price target on shares of Pulse Biosciences in a report on Friday, February 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $30.00.

Institutional Trading of Pulse Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in PLSE. Portolan Capital Management LLC purchased a new stake in shares of Pulse Biosciences during the 3rd quarter valued at $1,809,000. Brooklyn Investment Group raised its position in shares of Pulse Biosciences by 330.7% during the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after buying an additional 100,081 shares in the last quarter. Argo Wealth Advisory LLC purchased a new stake in shares of Pulse Biosciences during the 4th quarter valued at $387,000. Tudor Investment Corp ET AL purchased a new stake in shares of Pulse Biosciences during the 4th quarter valued at $382,000. Finally, UBS Group AG raised its position in shares of Pulse Biosciences by 53.4% during the 3rd quarter. UBS Group AG now owns 76,856 shares of the company’s stock valued at $1,360,000 after buying an additional 26,739 shares in the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.